中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2012年
35期
24-25
,共2页
瑞格列奈%老年 2 型糖尿病
瑞格列奈%老年 2 型糖尿病
서격렬내%노년 2 형당뇨병
Repaglinide%Elderly type 2 diabetic
目的探讨瑞格列奈治疗老年2型糖尿病的临床疗效及安全性.方法选择41例老年2型糖尿病患者,给予瑞格列奈0.5~4mg,于每日餐前口服,每日3次,按进餐时服药,不进餐时不服药的原则.每周调整一次剂量到稳定剂量,最高剂量12mg,治疗12周.治疗期间保持饮食,生活规律、运动基本一致.对治疗前后测定空腹血糖(FBG)、餐后2h 血糖(PBG2h)、糖化血红蛋白(HbA1c)及血胆固醇(TC)、血三酰甘油(TG)、及肝功(ALT)肾功(Cr BUN)、体质量指数(BMI).结果治疗前空腹血糖(FBG)、餐后2h 血糖(PBG2h)、糖化血红蛋白(HbA1c)分别为(8.4±1.0)mmol/L,(12.1±2.2)mmol/L,(9.30±1.98)%,治疗后分别为(6.70±0.93)mmol/L,(8.80±2.20)mmol/L,(6.8±1.07)%,治疗前后差异有统计学意义(P<0.05~0.01),无明显不良反应.结论瑞格列奈可迅速有效的控制血糖,不良反应轻微,是临床治疗老年2型糖尿病的理想药物.
目的探討瑞格列奈治療老年2型糖尿病的臨床療效及安全性.方法選擇41例老年2型糖尿病患者,給予瑞格列奈0.5~4mg,于每日餐前口服,每日3次,按進餐時服藥,不進餐時不服藥的原則.每週調整一次劑量到穩定劑量,最高劑量12mg,治療12週.治療期間保持飲食,生活規律、運動基本一緻.對治療前後測定空腹血糖(FBG)、餐後2h 血糖(PBG2h)、糖化血紅蛋白(HbA1c)及血膽固醇(TC)、血三酰甘油(TG)、及肝功(ALT)腎功(Cr BUN)、體質量指數(BMI).結果治療前空腹血糖(FBG)、餐後2h 血糖(PBG2h)、糖化血紅蛋白(HbA1c)分彆為(8.4±1.0)mmol/L,(12.1±2.2)mmol/L,(9.30±1.98)%,治療後分彆為(6.70±0.93)mmol/L,(8.80±2.20)mmol/L,(6.8±1.07)%,治療前後差異有統計學意義(P<0.05~0.01),無明顯不良反應.結論瑞格列奈可迅速有效的控製血糖,不良反應輕微,是臨床治療老年2型糖尿病的理想藥物.
목적탐토서격렬내치료노년2형당뇨병적림상료효급안전성.방법선택41례노년2형당뇨병환자,급여서격렬내0.5~4mg,우매일찬전구복,매일3차,안진찬시복약,불진찬시불복약적원칙.매주조정일차제량도은정제량,최고제량12mg,치료12주.치료기간보지음식,생활규률、운동기본일치.대치료전후측정공복혈당(FBG)、찬후2h 혈당(PBG2h)、당화혈홍단백(HbA1c)급혈담고순(TC)、혈삼선감유(TG)、급간공(ALT)신공(Cr BUN)、체질량지수(BMI).결과치료전공복혈당(FBG)、찬후2h 혈당(PBG2h)、당화혈홍단백(HbA1c)분별위(8.4±1.0)mmol/L,(12.1±2.2)mmol/L,(9.30±1.98)%,치료후분별위(6.70±0.93)mmol/L,(8.80±2.20)mmol/L,(6.8±1.07)%,치료전후차이유통계학의의(P<0.05~0.01),무명현불량반응.결론서격렬내가신속유효적공제혈당,불량반응경미,시림상치료노년2형당뇨병적이상약물.
Objective To investigate the repaglinide treatment of elderly patients with type 2 diabetes clinical efficacy and safety. Methods 41 cases of elderly patients with type 2 diabetes, given repaglinide 0.5 ~ 4mg, daily pre-dinner orally, 3 times a day, according to meal medication, medication principle without meals. The dose to be adjusted once a week stable dose, the highest dose of 12mg, 12 weeks of treatment. Diet during treatment, consistent patterns of life, sports. Before and after treatment, fasting blood glucose (FBG), 2 hours postprandial blood sugar (PBG2h), glycosylated hemoglobin (HbA1c) and blood cholesterol (TC), serum triglyceride (TG), and liver function (ALT), renal function (Cr BUN ), body mass index (BMI). Results Before treatment, fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG2h), glycosylated hemoglobin (HbA1c) were (8.4 ± 1.0) mmol/L (12.1 ± 2.2) mmol/L (9.30 ± 1.98)%, after treatment, respectively (6.70 ± 0.93) mmol/L (8.80 ± 2.20) mmol/L (6.8 ± 1.07)%, the difference was statistically significant (P<0.05 to 0.01) before and after treatment, no significant adverse reactions. Conclusion Repaglinide can quickly Conclusion effective control of blood glucose, adverse reactions are mild, it is ideal for the clinical treatment of elderly patients with type 2 diabetes drug.
